Centers for Medicare and Medicaid Services

Company

Related News

Drugmakers see little financial impact from Trump pricing deals

Big drug companies said Trump administration pricing deals had little to no noticeable impact on earnings, though details remain confidential. Novo Nordisk and Eli Lilly described bigger effects tied to lower GLP-1 cash-pay prices and expanded Medicare coverage.

Precigen Reports $3.4M in First PAPZIMEOS Sales, Secures Standard of Care Endorsement

Precigen reported $3.4 million in first commercial sales of PAPZIMEOS in Q4 2025 following FDA approval for recurrent respiratory papillomatosis. The drug has received standard of care endorsement from physician experts and now covers approximately 90% of insured U.S. lives. The company has $100.4 million in cash and is pursuing European regulatory approval.

Related Clinical Trials

NCT ID Title Status Phase
NCT06617533

Evaluation of the Primary Care First Model

ACTIVE_NOT_RECRUITING
NCT06616246

Training Community Members to be Coaches to Deliver the HealthyLifetime Program

RECRUITING NA
NCT05999084

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

RECRUITING
NCT04287738

Care Ecosystem: Navigating Patients and Families Through Stages of Care, Extension Trial

COMPLETED NA
NCT04057521

Coordinated HEalthcare for Complex Kids

COMPLETED NA
NCT04047147

Evaluation of the Million Hearts CVD Risk Reduction Model

UNKNOWN
NCT03411785

Evaluation of the Comprehensive Primary Care Plus (CPC+) Model

UNKNOWN NA
NCT03202745

The Effect of Informative Letters on the Prescription and Receipt of Opioids

WITHDRAWN NA
NCT03139019

Medicaid Incentives for the Prevention of Chronic Diseases: Diabetes Prevention

COMPLETED NA
NCT03018197

Use of Electronic Personal Health Records to Improve Medication Adherence

COMPLETED NA